These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15546017)

  • 1. Commentary on: Mobley AJ, Lam YW, Lau KM, Pais VM, Lesperance JO, Steadman B, et al. Monitoring the serological Proteome Colon, the latest modality in prostate cancer detection. J Urol 2004; 172: 331-7.
    Getzenberg RH
    Asian J Androl; 2004 Dec; 6(4):283. PubMed ID: 15546017
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80.
    Morgentaler A
    Eur Urol; 2007 Jul; 52(1):292; author reply 293-4. PubMed ID: 17400361
    [No Abstract]   [Full Text] [Related]  

  • 4. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
    J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Felix K.-H. Chun, Thomas Steuber, Andreas Erbersdobler, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-26.
    Beckley I; Khan MA
    Eur Urol; 2007 Oct; 52(4):1270; author reply 1271. PubMed ID: 17611016
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 7. Using spectral moments of spiral networks based on PSA/mass spectra outcomes to derive quantitative proteome-disease relationships (QPDRs) and predicting prostate cancer.
    Ferino G; González-Díaz H; Delogu G; Podda G; Uriarte E
    Biochem Biophys Res Commun; 2008 Jul; 372(2):320-5. PubMed ID: 18503754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human sperm proteome: the potential for new biomarkers of male fertility and a transformation in our understanding of the spermatozoon as a machine: commentary on the article 'Identification of proteomic differences in asthenozoospermic sperm samples' by Martinez et al.
    Barratt CL
    Hum Reprod; 2008 Jun; 23(6):1240-1. PubMed ID: 18305001
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 10. Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int. J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).
    Schulz RJ; Kagan AR
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207038
    [No Abstract]   [Full Text] [Related]  

  • 11. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
    Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
    Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Deprivation (AD) among low-risk and intermediate-risk prostate cancer patients: in regard to Ciezki et al. (Int J Radiat Oncol Biol Phys 2004;60:1347-1350).
    Oton CA
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):291-2; author reply 292. PubMed ID: 15850937
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Aurélien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol 2006;50:1248-53.
    Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L
    Eur Urol; 2007 Jul; 52(1):294-5. PubMed ID: 17383812
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B; Ball G; Rees R
    Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091.
    Brú A
    J Urol; 2007 Apr; 177(4):1585; author reply 1585-6. PubMed ID: 17382784
    [No Abstract]   [Full Text] [Related]  

  • 17. Biomarkers for prostate cancer.
    Makarov DV; Loeb S; Getzenberg RH; Partin AW
    Annu Rev Med; 2009; 60():139-51. PubMed ID: 18947298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood biomarkers for prostate cancer detection and prognosis.
    Shariat SF; Karam JA; Roehrborn CG
    Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Best practice statement on cryosurgery for the treatment of localized prostate cancer R. J. Babaian, B. Donnelly, D. Bahn, J. G. Baust, M. Dineen, D. Ellis, A. Katz, L. Pisters, D. Rukstalis, K. Shinohara and J. B. Thrasher J Urol 2008; 180: 1993-2004.
    Gans W
    J Urol; 2009 May; 181(5):2388. PubMed ID: 19303086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.